Benefits
Cardiovascular use in TCM and Chinese hospital practice
Most-used TCM herb for cardiovascular conditions over 2,000 years. Widely used in Chinese hospitals as IV preparations (Danhong, Salvianolate, Compound Danshen) for acute angina, MI, stroke. Hundreds of Chinese RCTs reported but methodological quality concerns: poor blinding, short duration, weak control conditions, language barriers. Mechanism robust (vasodilation, antiplatelet, antioxidant); clinical translation to oral Western use has not been demonstrated. The route matters here: the Chinese hospital preparations named above are given intravenously, so their results do not carry over to a capsule or a decoction taken by mouth.
Compound Danshen Dropping Pill (CDDP) for stable angina
CDDP — combination of Salvia miltiorrhiza + Panax notoginseng + Borneol — has multiple Chinese RCTs for stable angina pectoris suggesting symptomatic improvement. A 2025 narrative review in Medicine by Liu and Zhu pulled together 10 randomized trials and reported symptom benefit, but it is a perspective article rather than a graded systematic review, and an earlier overview of 13 systematic reviews covering 34,071 patients found the underlying trial quality only very low to moderate with hard endpoint benefit unproven. The important caveat for anyone shopping for danshen is that CDDP is not danshen: it is a three-ingredient patent drug, so its results cannot be read as evidence for a single-herb danshen supplement. Not widely available/marketed in Western markets but established as multi-million-dollar Chinese pharmaceutical product.
Negative Western trial in hypertension/dyslipidemia (Van Poppel 2015)
A Dutch double-blind randomized crossover trial used Salvia miltiorrhiza root water-extract (3 g/day for 4 weeks) in patients with hypertension and hyperlipidemia. Result: no beneficial effect on cardiovascular risk factors. Blood pressure, endothelial function, markers of inflammation, oxidative stress, glucose metabolism, hemostasis and blood viscosity were all unchanged, and LDL cholesterol was actually slightly higher after danshen than after placebo (3.82 versus 3.52 mmol/L), so the direction on the primary lipid outcome was unfavourable rather than merely null. Only 20 participants were analysed, and the study was funded by a commercial source, Cinmar Pharma. Important Western counterevidence to enthusiastic Chinese trial results, suggesting effects may depend on preparation type, population, formulation, or other factors not isolated in monotherapy oral testing.
In vitro and animal mechanistic support
Tanshinone IIA and salvianolic acids robustly demonstrate: ACE inhibition, vasodilation, antiplatelet activity, anti-inflammatory effects, antioxidant capacity, anticoagulant effects, mitochondrial protection, free radical scavenging. Mechanistic basis is strong; clinical translation is the gap. Used as a research compound in cardiovascular preclinical models extensively. All of the activities listed in this paragraph are cell and animal findings, so none of them is evidence that swallowing danshen does anything measurable in a person, and they are given here as background rather than as a benefit you should expect.
Antiplatelet activity (relevant to traditional 'blood-moving' uses)
Tanshinones inhibit platelet aggregation in vitro and in animal models — mechanistic basis for the traditional 'blood-moving' (huo xue) classification. This has not been shown to translate into a measured antiplatelet effect after oral danshen in people, since the one trial that measured hemostasis in oral danshen users found no change. It is listed here as a safety consideration rather than as a benefit, because the same property is what explains the documented warfarin INR elevation interactions — a real concern for safety in patients on anticoagulants.
Mechanism of action
ACE inhibition and angiotensin II reduction
Salvia miltiorrhiza components inhibit angiotensin converting enzyme (ACE), reducing angiotensin II levels and indirectly affecting atrial natriuretic peptide. This ACE activity has been shown in laboratory and animal work; it has not been shown to lower blood pressure in people taking oral danshen on its own, and danshen should not be thought of as a substitute for a prescribed ACE inhibitor. The one trial that recorded 24-hour ambulatory blood pressure on 3 g/day of oral danshen found no change at all, so treat this as a theoretical basis only.
Vasodilation via nitric oxide and calcium channel modulation
Tanshinones produce vasodilation via multiple mechanisms: NO synthesis enhancement, calcium channel modulation, smooth muscle relaxation. Improves coronary blood flow in animal models and in vitro. Underlies traditional applications for chest pain, stroke recovery, peripheral vascular conditions.
Antiplatelet effects via thromboxane reduction
Tanshinones inhibit platelet aggregation by reducing thromboxane A2 production and modulating COX-1 pathway. This is a laboratory finding and is not a demonstrated effect of oral danshen in people; danshen is not an alternative to aspirin or to any prescribed antiplatelet drug. Clinically important for both traditional 'blood-moving' indication and for warfarin interaction concerns.
Antioxidant and anti-inflammatory pleiotropic effects
Salvianolic acids increase SOD, catalase, GPx, GSH levels; reduce lipid peroxidation and inflammatory cytokines. Combined antioxidant + anti-inflammatory effects relevant to ischemia-reperfusion injury (the rationale for IV use in acute MI/stroke in Chinese hospitals). Mechanism strong; standalone oral consumer product effect size unclear.
Clinical trials
Randomized double-blind cross-over trial (van Poppel PCM, Breedveld P, Abbink EJ, Roelofs H, van Heerde W, Smits P, Lin W, Tan AHA, Russel FG, Donders R, Tack CJ, Rongen GA 2015, PLoS One 10(6):e0128695, doi:10.1371/journal.pone.0128695). NCT01563770.
Twenty analysed participants aged 40 to 70 with hypertension and hyperlipidemia, recruited by newspaper advertisement. Randomized to 3 capsules of 500 mg Salvia miltiorrhiza extract twice daily (3 g/day) OR placebo for 4 weeks each in crossover design. Endpoints: lipid profile, BP, endothelial function, oxidative stress, inflammation, hemostasis, insulin sensitivity.
No beneficial effect on cardiovascular risk factors. LDL cholesterol was significantly higher after danshen than after placebo (3.82 versus 3.52 mmol/L), and blood pressure, endothelial function, markers of inflammation, oxidative stress, glucose metabolism, hemostasis and blood viscosity were all unchanged. Only 20 participants were analysed. The study was funded by a commercial source (Cinmar Pharma), which makes a bias against danshen unlikely. Authors concluded: 'Salvia miltiorrhiza root water-extract has no beneficial effect on cardiovascular risk factors.' Important Western counterevidence to Chinese trials. Authors noted: quality of Chinese clinical trials of Danshen is poor; not easily accessible to Western physicians as most published in Chinese — explanation for evidence base disconnect.
Narrative perspective review of 10 randomized trials (Liu XF, Zhu XX 2025, Medicine (Baltimore) 104(16):e42175), read alongside an earlier overview of 13 systematic reviews of the same product covering 34,071 patients (Luo 2015) and a systematic review of 7 trials in acute myocardial infarction (Luo 2013).
Reviews of multiple Chinese clinical trials of Compound Danshen Dropping Pill (Salvia miltiorrhiza + Panax notoginseng + Borneol) for stable angina pectoris. Comparator: standard pharmacological treatments (nitrates, beta-blockers, calcium channel blockers).
CDDP demonstrated symptomatic improvement in angina pectoris in multiple Chinese clinical trials — though most have methodological limitations (blinding concerns, short duration, weak controls). Establishes a clinical use case for combination danshen formulas rather than for danshen on its own. The overview of 13 systematic reviews graded the underlying evidence very low to moderate and found benefit on hard endpoints unproven, and the systematic review of the pill after acute myocardial infarction likewise rated its evidence low to moderate and could not confirm the product's safety. Because CDDP contains Panax notoginseng and borneol as well as danshen, none of this can be credited to danshen alone. Notable: traditional Chinese use is almost always in combination — Western monotherapy testing may not reflect optimal use.
Comprehensive pharmacology review (Adams JD, Wang R, Yang J, Lien EJ 2006, Chin Med 1:3, doi:10.1186/1749-8546-1-3).
Review of preclinical and clinical examinations of Salvia miltiorrhiza and tanshinones in ischemic conditions including angina, heart attack, stroke.
Documented robust preclinical evidence for: ACE inhibition, vasodilation, antiplatelet activity, anti-inflammatory effects, antioxidant capacity. Clinical evidence assessed across preparation types, doses, blinding, controls. Authors noted methodological limitations of available trials and emphasized need for more rigorous Western-standard clinical trials. Established the central tension in danshen evidence: strong mechanism and long traditional use versus limited rigorous modern trial validation. This is a narrative review, not a trial, so nothing in it counts as clinical proof, and the clinical studies it surveys were published largely in China and cover a range of danshen preparations rather than the oral single-herb extract sold as a supplement in the West.